Figure 7From: Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125 Effects of targeted cytotoxic LHRH analog, AEZS-108, at doses equivalent to 1.45 mg/kg DOX and the radical DOX (administered i.v. on days 1, 7, 14) at equimolar doses on the growth HCC-1806 human TNBC (mean ± se). (* = p < 0.05 two sided Student’s t-test).Back to article page